The primary interest of my laboratory is focused on the identification of the genetic basis of cancer susceptibility. A key question in these efforts is how the germline genetic events contributing to predisposition of human cancers interact mutually in particular molecular pathways or in concert with the environmental exposures. Specifically, our ongoing studies aim at identification of the genetic variants conferring an increased risk to common cancers, such as breast, colon, prostate cancers or lymphoma, focusing on the relevant molecular pathways. These studies combine the genome-wide association analysis (GWAS), high-throughput genotyping and most recently the next-generation sequencing in large case/control populations. The significant aspect of my current and future research is an integration of the information from somatic genetics in tumors to complement the germline findings. We believe that such integration of biological data will be beneficial not only for improved prevention strategies but most importantly for the future development of the targeted personalized therapies.
Associate Professor, Department of Population Health
Associate Professor, Department of Environmental Medicine
Journal of the National Cancer Institute. 2018 Jun 15;
PLoS one. 2018 May 30; 13(5):e0198119-e0198119
Journal of translational medicine. 2018 Apr 02; 16(1):82-82
BMC public health. 2018 Jan 05; 18(1):101-101
Germline determinants of immune related adverse events (irAEs) in melanoma immunotherapy response [Meeting Abstract]
Annals of oncology. 2017 SEP; 28:?-?
PLoS one. 2017 Aug 29; 12(8):e0182483-e0182483e0182483
Journal of clinical & translational endocrinology. 2017 Aug 14; 10:1-8
Mutation burden as a potential prognostic marker of melanoma progression and survival [Meeting Abstract]
Journal of clinical oncology. 2017 Jun 20; (2017):